Answer
It is an autologous CD19-directed CAR T-cell therapy: the patient’s own T cells are collected, genetically modified and returned by intravenous infusion to target B-cell lymphoma cells.
Sources for this answer
- Breyanzi 1.1-70 × 10^6 cells/mL / 1.1-70 × 10^6 cells/mL dispersion for infusion — Current selected SmPCemc · Summary of Product Characteristics
- NHSNHS · NHS medicine guidance